ReviewVaccine: X2025
Current status of the development of dengue vaccines.
Review in Vaccine: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities.Human vaccines & immunotherapeutics · 2026Review
- A gut commensalVirulence · 2026Article
- Dengue vaccination Knowledge, Attitudes, and Practices among healthcare providers in selected countries from Latin America and Asia Pacific.Human vaccines & immunotherapeutics · 2026Article
- Arboviral infections of the central nervous system: Mechanisms of invasion and long-term consequences.Journal of neurovirology · 2026Review
- Insecticide resistance in mosquitoes: Current status, mechanism, monitoring and innovative strategies for sustainable vector control.Molecular biology reports · 2026Review
- Computational discovery of DENV-3 RdRp allosteric inhibitors: biological evaluation and mechanistic studies.Molecular diversity · 2026Article
- The Role of Natural Killer (NK) Cells in Dengue Virus Infection: A Narrative Review.Health science reports · 2026Article
- Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.Scientific reports · 2026Article
- Designing potent and immunogenic epitope based peptide vaccine against all serotypes of DENV via structural, physico-chemical and immunoinformatics-based approaches.Scientific reports · 2026Article
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- Dengue virus genetic diversity and lineage dynamics in Thailand: implications for surveillance and vaccine implementation.Virology journal · 2026Article
- Bridging laboratory and field research: Method adjustments to blood feed field-derived Aedes aegypti.PLoS neglected tropical diseases · 2026Article
- The need for balanced dengue vaccine protection: Insights from Thai surveillance data on four serotypes.PLoS neglected tropical diseases · 2026Article
- Computational identification of conserved dengue virus envelope protein epitopes for vaccine design and immunodiagnostic platform.Scientific reports · 2026Article
- Sulfonyl Anthranilic Acid Analogues Display Pan-Serotype Anti-Dengue Activity by Downregulating the Expression of Ribosomal Proteins Encoded by 5'-Terminal Oligopyrimidine Motif-Containing mRNA.Journal of medicinal chemistry · 2026Article
- Addressing Knowledge, Attitudes and Practices Toward Dengue Fever, Vector Control, and Vaccine Acceptance Among the General Population in Singapore.Tropical medicine and infectious disease · 2026Article
- Protease Inhibitors and Innate Immune Agonists as Antiviral Strategies Against Dengue and Zika Viruses.Pathogens (Basel, Switzerland) · 2026Review
- From promise to pitfalls: immunological lessons from dengue vaccines and their implications.NPJ vaccines · 2026Review
- Dengue Fever Diagnosis: Performance Characteristics of Current Tests and Emerging Detection Technologies.Molecular diagnosis & therapy · 2026Review
- Impact of Specific Pattern Mutations on Plaque Formation and Attenuation Properties of Dengue Virus Serotype 3.Advances in virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue fever is caused by the mosquito-borne dengue virus (DENV), which is endemic in more than 100 countries. Annually, there are approximately 390 million dengue cases, with a small subset manifesting into severe illnesses, such as dengue haemorrhagic fever or dengue shock syndrome. Current treatment options for dengue infections remain supportive management due to the lack of an effective vaccine and clinically approved antiviral. Although the CYD-TDV (Dengvaxia®) vaccine with an overall vaccine efficacy of 60 % has been licensed for clinical use since 2015, it poses an elevated risk of severe dengue infections especially in dengue-naïve children below 9 years of age. The newly approved Qdenga vaccine was able to achieve an overall vaccine efficacy of 80 % after 12 months, but it was not able to provide a protective effect against DENV-3 in dengue naïve individuals. The Butantan-DV vaccine candidate is still undergoing phase 3 clinical trials for safety and efficacy evaluations in humans. Apart from live-attenuated vaccines, various other vaccine types are also currently being studied in preclinical and clinical studies. This review discusses the current status of dengue vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.